Impella 5.5 Support Beyond 50 Days as Bridge to Heart Transplant in End-Stage Heart Failure Patients
- 5 August 2022
- journal article
- case report
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (4) , e158-e162
Abstract
Prolonged mechanical circulatory support (MCS) for severe left ventricular dysfunction in cardiogenic shock as a bridge to heart transplantation (HTx) generally requires a surgical procedure. Typically, a surgically implanted temporary extracorporeal left ventricular assist device (LVAD) is chosen because of superior flow and durability compared with a percutaneously delivered endovascular LVAD (pVAD). However, compared with its predecessors, the Impella 5.5 trans-valvular pVAD provides higher hemodynamic support and features improved durability. Here, we present four successful cases with prolonged Impella 5.5 support as a bridge to HTx, with a mean support duration of 70 days (maximum 83 days). These cases highlight several potential benefits of Impella 5.5. The minimally invasive implantation procedure of the device reduces bleeding, decreases the postoperative recovery period, and enables early patient ambulation to reduce physical deconditioning before HTx surgery. Furthermore, Impella 5.5 adequately unloads the left ventricle and provides hemodynamic support to maintain end-organ function to further optimize hemodynamics before HTx. The evolution of Impella 5.5 technology may provide an alternative bridging strategy to traditional surgically implanted temporary MCS in select cases.Keywords
This publication has 13 references indexed in Scilit:
- New Surgical Circulatory Support System OutcomesASAIO Journal, 2020
- Reduced Rethoracotomy Rate for Bleeding and Postoperative Hospital Stay with Less Invasive Ventricular Assist Device Implantation, Multicenter ExperienceThe Journal of Heart and Lung Transplantation, 2020
- Complete Sternal-Sparing Approach Improves Outcomes for Left Ventricular Assist Device Implantation in Patients With History of Prior SternotomyInnovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2020
- Clinical Outcomes of Impella Microaxial Devices Used to Salvage Cardiogenic Shock as a Bridge to Durable Circulatory Support or Cardiac TransplantationASAIO Journal, 2019
- Minimally Invasive versus Conventional LVAD-Implantation—An Analysis of the LiteratureThe Thoracic and Cardiovascular Surgeon, 2018
- Maximum level of mobility with axillary deployment of the Impella 5.0 is associated with improved survivalThe International Journal of Artificial Organs, 2018
- Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user groupInternational Journal of Cardiology, 2015
- The impact of extended bed rest on the musculoskeletal system in the critical care environmentExtreme Physiology & Medicine, 2015
- IMPROVED EARLY MOBILIZATION WITH AXILLARY IMPLANT OF THE IMPELLA DEVICE: INSIGHTS FROM A DUAL CENTER CANADIAN EXPERIENCECanadian Journal of Cardiology, 2015
- Temporary Left Ventricular Assist Device Through an Axillary Access is a Promising Approach to Improve Outcomes in Refractory Cardiogenic Shock PatientsASAIO Journal, 2015